UNSPSC 51141519: Mephenytoin

This classification denotes an anticonvulsant agent with the molecular formula C12H14N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R420KW629U, chemically known as 2,4-imidazolidinedione, 5-ethyl-3-methyl-5-phenyl- but generally known as mephenytoin, which bears US NIH Compound Identifier 4060. European Medicines Agency schedules Mephenytoin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08749MIG.

UNSPSC 51141519 Mephenytoin, a Commodity code, nominally designates a specific anticonvulsant pharmaceutical, but recent state and local procurement activity under this code shows little direct alignment with the product name. Instead, the opportunities posted reflect broader pharmaceutical procurement by health agencies — naloxone and drug deactivation systems for emergency response and overdose intervention, direct-to-manufacturer prescription programs for state employee health plans, and multi-source generic pharmaceuticals and OTC products distributed through cooperative purchasing. The scope of work spans emergency medical supplies, prescription fulfillment logistics, and bulk pharmaceutical distribution to state and local health facilities. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and state procurement offices administering cooperative purchasing consortia (Minnesota Department of Administration through MMCAP). The code shows activity across health agencies managing public health initiatives, employee benefits programs, and multi-jurisdictional pharmaceutical supply chains.

Recent opportunities cluster in the South and Midwest. Seminole County, Florida posted an IFB on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida, with a response deadline of July 26, 2023 (note: the date appears inconsistent in the source). The Texas HHS Commission issued a Request for Information on April 3, 2026, to explore direct-to-manufacturer prescription contracting outside traditional pharmacy benefit manager channels. MMCAP, administered by Minnesota's Department of Administration, released an RFP on January 20, 2026, seeking manufacturers of generic multi-source pharmaceuticals and OTC products for distribution across state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026. Vendors pursuing opportunities under this code should expect requirements for FDA compliance, Good Manufacturing Practices certification, Drug Supply Chain Security Act adherence, and substantial insurance coverage including commercial general liability minimums in the $2 million to $5 million range.